Geneoscopy Inc., an innovative life sciences company dedicated to advancing gastrointestinal health diagnostics, has successfully raised $105 million in its latest funding round. This significant investment will be pivotal in accelerating the development and commercialization of Geneoscopy's groundbreaking diagnostic tests, including their FDA-approved ColoSenseâ„¢ test. Utilizing a unique proprietary platform based on stool-derived eukaryotic RNA (seRNA), Geneoscopy aims to empower both patients and healthcare providers with transformative tools for early detection and monitoring of colorectal cancer and advanced adenomas in average-risk individuals aged 45 and older. The funds will support further research initiatives, enhance product development, and expand Geneoscopy's collaborative projects with leading universities and biopharmaceutical partners, as they work towards creating innovative diagnostics for other gastrointestinal diseases. With a strong commitment to improving patient outcomes and streamlining gastrointestinal health management, Geneoscopy intends to leverage this new capital to bring its proprietary technologies to the forefront of the industry. As they embark on this exciting new chapter of growth, Geneoscopy continues to focus on their mission to revolutionize gastrointestinal diagnostics, making it easier and more efficient for patients to access life-saving information. For updates on their journey, follow Geneoscopy on LinkedIn or visit www.geneoscopy.com.
Geneoscopy Secures $105 Million in Series C Round to Advance Gastrointestinal Health through Innovative Diagnostic Tests
Recently funded · $105.0M Series cHealthcare
Get the full Geneoscopy company profile
Access contacts, investors, buying signals & more
Other recently funded companies
View all
Laihua Online
Wuhan Laihua Information and Technology is an Internet leading source of information on educational opportunities for students to study in other countries especially in China. Either prospect is planning to come to China or is already in China for education (self-support or scholarship based) he will probably need one of the ranges of services we provide from Education, Translation, Notarization of legal documents to Internships & Jobs or Medical Tourism etc. It is a comprehensive directory of study abroad programs, including summer study abroad, service learning, intensive language programs and more. Wuhan Laihua Information and Technology first set out to fill the information gap between students with a desire to travel abroad to study and companies offering international programs.
$68.0M Series d
today
NEW ID
NEW ID is the latest subsidiary company of NEW, which has started up since August 2019 for a new digital contents/platform business domain. We are responsible for expanding the contents produced and acquired by NEW into various markets and creating our digital capabilities through partnering with a-lister digital content creators and providers in Korea.
Other recent Series c rounds
Companies that recently closed a Series c round.
| # | Company | Round | Amount | Date |
|---|---|---|---|---|
| 1 |  SOLIVIS | Series c | $16.0M | 1d ago |
| 2 |  SKAN Switzerland | Series c | $63.0M | 1d ago |
| 3 |
